Role of Chromogranin A and Neuron-Specific Enolase Biomarkers in Progression-Free Survival (PFS) with Everolimus (EVE) v. Placebo (PB) in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET): Phase III RADIANT-3 Results
#341
Introduction: In previous phase II studies of EVE in patients with pNET, those with elevated baseline Chromogranin A (eCgA) and neuron-specific enolase (eNSE) levels experienced shorter PFS.
Aim(s): To evaluate the effect of EVE in pNET patients with elevated v. non-elevated CgA and NSE, and their association with PFS in a randomized trial.
Materials and methods: In RADIANT-3 (EVE 10mg/d [n=207] v. PB [n=203]), serum CgA and NSE were measured at baseline and monthly thereafter if > upper limit of normal (ULN). Patients were categorized by CgA and NSE level (elevated or non-elevated). Cut-off values for elevated baseline were 2×ULN CgA (eCgA, 72.8ng/mL) and >ULN NSE (eNSE, 8.6ng/mL).
Conference: 8th Annual ENETSConcerence (2011)
Presenting Author:
Authors: Oberg K, Anthony L, Sideris L, Chen L, Cherfi A,
Keywords: mTOR, everolimus, chromogranin A, neuron-specific enolase, pancreatic neuroendocrine tumors,
To read the full abstract, please log into your ENETS Member account.